Objective: To assess the antihypertensive efficacy of olmesartan medoxomil and ramipril on 24-h ambulatory blood pressure (ABP) in elderly hypertensive patients by pooled data analysis of two studies with identical designs (one Italian, one European).
INTRODUCTION

I
n hypertensive patients, and in particular in the elderly, maintenance of blood pressure (BP) control throughout the entire 24-h period is important, in order to avoid excessively high BP at night and at awakening, which may trigger cardiovascular events [1] [2] [3] [4] . Choice of longacting antihypertensive agents, providing consistent control throughout a 24-h dosing interval, is thus particularly important in this high-risk age category, even more than in young hypertensive patients [5] . Ambulatory blood pressure (ABP) monitoring is required to verify whether such a BP control is achieved over the 24 h [6] .
Oral olmesartan medoxomil, at doses ranging between 10 and 40 mg once-daily, is a long-acting angiotensin II receptor blocker (ARB) [7] , and long-acting ARBs are recommended by current guidelines as possible option as a first-line treatment of adult patients with arterial hypertension, also including elderly individuals [5] . Efficacy of olmesartan has been extensively demonstrated in elderly hypertensive patients, by means of large well designed trials [8] [9] [10] . Recently, two double-blind, randomized, parallel-group studies with identical design have additionally shown that olmesartan 10-40 mg is superior to ramipril 2.5-10 mg in controlling not only office, but also ABP of elderly individuals, aged 65-89 years, with grade 1 or 2 essential hypertension [11, 12] . These were in absolute the first head-to-head trials comparing an angiotensinconverting enzyme (ACE)-inhibitor and an ARB in elderly hypertensive patients.
Additional use of ABP monitoring in the two studies allowed better evaluation not only of the magnitude of the antihypertensive activity of both drugs, but also of its distribution and homogeneity over the 24 h. This allowed to show a better antihypertensive control of olmesartan particularly in the last hours of the dosing interval [11, 12] . However, ABP was not the primary measure in both studies and a detailed analysis of the drugs within the dosing interval or in subgroups of patients was not performed in the main publications.
The objective of the present pooled analysis of the individual data of the subgroup of patients with valid ABP recordings of the two recently published double-blind, randomized, parallel-group studies with an identical design, one performed in Italy and one in several European countries, was to compare the efficacy of olmesartan and ramipril in elderly hypertensive patients [11, 12] .
METHODS
Study population
Elderly (age between 65 and 89 years) outpatients of both sexes, with grade 1 or 2 essential hypertension (sitting office DBP between 90 and 109 mmHg and/or office SBP between 140 and 179 mmHg after 2 weeks of wash-out with placebo) were eligible for study participation.
The study was conducted according to Good Clinical Practice guidelines and the Declaration of Helsinki, and the protocol was approved by the Ethics Committees of the centers involved. Written informed consent was obtained from all patients prior to their inclusion into the study.
Further details on inclusion and exclusion criteria as well as on study design can be derived from the original publications of the two studies [11, 12] .
Study design
The two studies had an identical multicenter, randomized (1 : 1), double-blind, parallel-group design. In one study [11] all participating centers were located in Italy (102 centers); in the second [12] , study centers were located in eight European countries (three in Austria, one in Belgium, two in France, 10 in Germany, two in Greece, one in Ireland, six in Poland and six in Spain). After 2 weeks of placebo wash-out from previous treatment, eligible patients were randomized and double-blind to 12 weeks of treatment with olmesartan medoxomil or ramipril at the initial doses of 10 or 2.5 mg, respectively, given once-daily (between 0900 and 1100 h). After the first 2 and 6 weeks of active treatment the drug dose had to be doubled if office SBP was greater than 140 mmHg or office DBP was at least 90 mmHg in nondiabetic patients or if office SBP was at least 130 mmHg or office DBP was at least 80 mmHg in diabetic patients, up to a maximum of 40 mg for olmesartan medoxomil and 10 mg for ramipril. Physical examination, BP and heart rate measurements were done at each visit, whereas a 12-lead ECG and blood samples for routine exams were taken at the randomization and final visits. BP was measured by a physician in the office using a standard mercury sphygmomanometer approximately 24 h after the last drug intake, taking three measurements, at 2 min intervals, after 5 min of rest in the sitting position.
Ambulatory blood pressure measurement
Ambulatory blood pressure monitoring was performed noninvasively over the 24 h by an oscillometric validated device [13, 14] , at randomization and at the final visit of the double-blind period (week 12). Current International Guidelines were followed for proper recording performance [15] . The monitoring cuff was wrapped around the nondominant arm and the patient was asked to keep her/ his arm still during the automatic BP measurements. The device was programmed to measure BP every 15 min during daytime (from 0600 to 2200 h) and every 30 min during night-time (2200 to 0600 h). Each recording started in the morning, immediately after office BP assessment and administration of treatment. Patients were then sent home, asked to resume normal life, and to come back 24 h later for removal of the device.
Data analysis
The analysis of 24-h BP recordings was preceded by removal of artifacts according to previously described editing criteria [16] . Recordings were considered valid when no more than 1 h was missing over the 24 h and when at least 70% of expected measurements were available.
Analysis was based on an intention-to-treat approach and performed on patients with valid 24-h ABP recordings at baseline and at the end of the 12 weeks of double-blind treatment, even in the presence of major protocol violations.
The following variables were considered in the analysis: changes in 24-h, daytime and night-time average SBP and DBP after treatment; SBP and DBP changes in the last 6 h of the dosing interval after treatment; hourly averages of SBP and DBP before and at the end of treatment; smoothness index of SBP and DBP after treatment; changes in the morning surge after treatment.
The smoothness index, used to assess the homogeneity of BP control, was computed for each patient by dividing the average of the 24-hourly BP changes after treatment by the corresponding standard deviation (SD) [17] [18] [19] . This index is characterized by a normal distribution and a greater reproducibility than the usually employed trough-to-peak ratio, thus having the advantages for the description of the consistency of the BP control over the 24 h also in individual patients.
The morning surge was computed as the difference between the lowest SBP values during night sleep (average of three readings centered around the lowest night-time value) and the average SBP in the 2 h around awakening (fixed time window between 0600 and 0800 h) [2] . According to available evidence, an excessive morning surge is a marker of increased risk of cardiovascular events and should be appropriately blunted by treatment [20, 21] .
Homogeneity of baseline demographic and clinical variables between the individual data of the two studies was assessed by analysis of variance or chi-squared test. An analysis of covariance considering study-and-treatment effect and their interaction was used to test homogeneity of treatment effects between studies. As shown in the results, such a homogeneity test did not result in any statistically significant difference between randomization groups. This allowed us to proceed with an analysis of individual pooled data rather than with a less robust metaanalysis of average data from the two studies. This was possible also because individual data were available for such an approach.
Between-treatment differences in mean ambulatory SBP and DBP changes and morning surge at week 12 of the double-blind period were assessed by analysis of covariance, by adjusting for the baseline value. Analysis of variance was used to assess differences in smoothness indices. Comparison of categorical variables was made by a Chi-square test. Subgroup analysis according to age and sex, and presence of sustained hypertension was also made. Sustained hypertension was defined by the concomitant occurrence of elevated office (SBP !140 mmHg and/or DBP !90 mmHg) and ABP (24 h average value of SBP !130 mmHg and/or DBP !80 mmHg) [15, 16] . Patients with elevated office BP, but normal 24-h average BP were classified as having isolated clinic hypertension, and removed from the subgroup analysis of sustained hypertensive patients [15, 16] . Correlations were sought between clinic and ABP values before and during treatment, in order to extend information on the similarities and discrepancies between these two different measures of the effect of antihypertensive treatment.
The level of statistical significance was kept at 0.05 throughout the whole study. Data are shown as mean AE SD or as mean and 95% confidence interval (CI).
RESULTS
Baseline demographic and clinical data
Overall, 1661 patients were screened, 1453 randomized and 1150 performed an ABP recording, in the two studies altogether [11, 12] . Seven hundred and fifteen of the patients undergoing ABP monitoring at baseline had valid recordings and no major protocol violations at the end of study, and were thus included in the intention-to-treat analysis (356 randomized to olmesartan medoxomil and 359 to ramipril).
Comparison of the baseline clinical characteristics of the patients of the two different studies showed that patients of the international study [12] were slightly, but significantly, more overweight, had slightly higher office SBP and DBP values, and were more frequently under antihypertensive treatment, with a larger previous use of beta-blockers and a lower use of alpha-blockers in the European study (Table 1) . However, as shown in Table 2 , when data from the two studies were pooled together, the two randomization groups were not significantly different at baseline with regards to demographic and clinical characteristics, except for a borderline significant difference in previous use of calcium channel blockers (slightly more frequent in the patients randomized to olmesartan). Data are separately shown and compared (P values) for the two studies and summarized as mean (AESD) or absolute (n) and relative frequency (%). ACE, angiotensin-converting enzyme.
Olmesartan vs. ramipril and ambulatory blood pressure
Journal of Hypertension www.jhypertension.com
Study drug doses
A significantly larger proportion of patients took the full drug dose in the ramipril than in the olmesartan group (54.9 vs. 41.6%; P ¼ 0.002). At the end of the study 23.9% and, respectively, 17.5% of patients were under the initial doses of olmesartan and ramipril (10 and 2.5 mg), and 34.6 and 27.6% under the intermediate doses of olmesartan and ramipril (20 and 5 mg). The average study drug dose at final visit was 25.9 AE 12.5 mg for olmesartan (65% of the maximal dose) and 7.3 AE 3.1 mg for ramipril (73% of the maximal dose). These findings were in line with those of the two main studies [11, 12] .
Main efficacy results
Both drugs reduced SBP and DBP during the whole 24 h as well as during the two main subperiods in which the 24 h were subdivided (daytime and night-time).
As mentioned in the methods, a homogeneity test considering study-and-treatment interaction did not show any statistically significant difference between the ABP effects of the two studies (P ¼ 0.691 24 h SBP; P ¼ 0.428 24 h DBP; P ¼ 0.728 daytime SBP; P ¼ 0.533 daytime DBP; P ¼ 0.457 night-time SBP; P ¼ 0.252 night-time DBP). In all instances baseline-adjusted reductions were always significantly larger with olmesartan than with ramipril (Fig. 1a) . Between-treatment differences (least-square means and 95% CIs) are reported in Table 3 . Drug treatment reduced BP also during every hour of the 24 h (P < 0.0001 for SBP and DBP, and for both olmesartan and ramipril), with most of the efficacy displayed in the first hours being maintained in the hours farthest from the last drug intake (Fig. 2) . This was particularly evident for olmesartan, for which significantly greater SBP and DBP reductions were observed in the last 6-h period from the dosing interval, covering the last part of the night sleep and the hours of awakening (Fig. 1a,  Fig. 2 and Table 3 ). In addition, olmesartan effectively blunted the BP morning rise, whereas this was not the case for ramipril (P < 0.01 between-treatments; Fig. 3 ).
The optimal BP control achieved by olmesartan over the dosing interval was confirmed when the homogeneity of this control was quantified by the smoothness index, which was significantly higher with this drug than with ramipril, for both SBP and DBP (Fig. 4, left panel) .
Patients with sustained or isolated clinic hypertension
Overall, 582 of the 715 patients (81.4%) had sustained hypertension, namely an elevation in both office and ABPs, with an equally distributed proportion between the two groups (80.6% in the olmesartan and 82.2% in the ramipril group), and with a greater prevalence of this condition in the patients of the European study (91.8 vs. 80.0% Italian study; P ¼ 0.009). As displayed in Fig. 1b , in sustained hypertensive patients, baseline-adjusted SBP and DBP reductions were larger than in the whole study group, and always significantly greater with olmesartan than with ramipril, except for night-time DBP. This was the case also for the morning surge, reduced by olmesartan, but not by ramipril (Fig. 3) . Between-treatment statistically significant differences were observed in this category of patients also for the smoothness index, this confirming the better distribution of BP control over the 24 h with olmesartan (Fig. 4 , Data are separately shown for the two treatment groups and reported as mean (AESD) or absolute (n) and relative frequency (%). P values refer to the statistical significance of the between-treatment difference. ACE, angiotensin-converting enzyme.
right panel). Interestingly, also in patients with isolated clinic hypertension a small antihypertensive effect was observed particularly for olmesartan, but this was never significantly different from that observed for ramipril (data not shown). Table 5 in the two separate treatment arms and in all patients pooled together, there was a significant but not very close relationship between office and 24-h BP both at baseline and at the end of the 12-week double-blind treatment. An even weaker 
Age and sex subgroups
DISCUSSION
Our pooled analysis of individual data of two previously published randomized, double-blind, parallel-group studies [11, 12] confirms that BP control of elderly hypertensive patients is larger and better maintained over the 24 h with olmesartan 10-40 mg once-daily than with ramipril 2.5-10 mg once-daily. After 12 weeks of treatment, olmesartan showed a better antihypertensive activity under normal daily living conditions and a greater duration and homogeneity of the BP reduction. Olmesartan was also superior to ramipril during the last 6 h of the dosing interval and in the early morning hours, confirming in a large sample of elderly hypertensive patients what shown in a pooled analysis of two open-label studies including 1613 grade 1-2 adult hypertensive patients treated for 14 weeks with another long-lasting ARB [22] . In the latter analysis SBP and DBP reductions with telmisartan 80 mg during the last 6 h of the once-daily dosing interval were larger than those observed with ramipril 5 or 10 mg. Also in our study the SBP and DBP reduction attained in the last 6 h with the long-acting ARB olmesartan significantly exceeded by 3.6 and 2.0 mmHg, respectively, than that of ramipril. To note that the superior antihypertensive effect of olmesartan was achieved despite the less frequent use of the highest drug dosage (43% of patients taking 40 mg/day) as compared to ramipril (52% of patients taking 10 mg/day). This is the first head-to-head comparison trial of an ARB and an ACE inhibitor in a large sample of elderly hypertensive patients undergoing 24-h ABP monitoring. Indeed, evidence of such a comparison is available from the literature only for few small-sample-sized studies, with a variable duration ranging between 4 and 24 weeks. In two of these trials the mean changes in 24-h average SBP and DBP with an ARB (telmisartan 20, 40 or 80 mg or candesartan 16 or 32 mg) were similar to those observed with an ACE inhibitor (enalapril 5, 10 or 20 mg or lisinopril 20 or 40 mg, 190 patients overall) [23, 24] . In two other trials the ARB (telmisartan 80 mg alone or combined with hydrochlorothiazide 12.5 mg) produced a significantly greater reduction in ABP than the ACE inhibitor (lisinopril 20 mg and hydrochlorothiazide 12.5 mg or ramipril) [25, 26] .
Our study also represents the first large, double-blind, randomized clinical trial assessing olmesartan monotherapy efficacy throughout the 24 h in elderly individuals. The only trial available so far is an open-label noncomparative trial based on a smaller sample size of patients (n ¼ 150), treated for 12 weeks with a combination of olmesartan 20 or 40 mg and hydrochlorothiazide 12.5 or 25 mg [27] . Notwithstanding differences in the study design, it is noteworthy that in this study 94% of the overall 24-h antihypertensive activity was still evident in the last 6 h, confirming the good persistence of the antihypertensive control observed in our study, in which 95% of the BP reduction over the 24 h was evident in the last 6 h, with 42% of patients under high dose olmesartan monotherapy (40 mg).
As compared to the original studies, the joint analysis offers several additional information on the efficacy of olmesartan vs. ramipril over the 24 h. In particular, the increased sample size derived from pooling together data from the two studies with a similar design, allowed important subgroups analyses, such as those in sustained hypertensive patients, and the assessment of additional variables of interest, such as the morning surge. The relevance of these new findings is discussed in the next paragraphs.
Olmesartan, but not ramipril, effectively buffered the early morning BP rise, which can be excessively increased in elderly patients with hypertension, this being associated with an increased risk of cardiovascular events [2, [28] [29] [30] [31] [32] [33] . Reduction of the morning surge may thus be a therapeutic target for preventing target organ damage and subsequent cardiovascular events in elderly hypertensive patients. In order to effectively reduce the magnitude of the early morning BP surge and related cardiovascular risk notably, a long-acting drug therapy is often necessary, because the time of the trough plasma drug level and therefore the lowest pharmacodynamic effect usually coincides with early morning rise in BP and heart rate [33] . Evidence of specific antihypertensive drug activity on morning surge as assessed by ABP monitoring is scanty, with no such data available for the elderly population [34] [35] [36] [37] .
We also assessed the antihypertensive effect of the two drugs in a large sample of elderly individuals with concomitant office and ambulatory (sustained) hypertension. Also in this subgroup of patients, potentially more resistant to the effect of treatment, both drugs reduced ABP, and olmesartan caused a larger BP decrease than ramipril. The only direct comparison of an ARB and an ACE inhibitor in confirmed ambulatory hypertensive patients available in the literature refers to a limited sample of adult patients (n ¼ 35) [38] . In this study 8-week treatment with telmisartan 80 mg provided significant reductions in 24-h average SBP and DBP, whereas this was not the case for ramipril. In our study the effect of the antihypertensive treatment was greater on office than on ABP and the relationship between the two pressures was weak. This is in line with and strengthens the evidence reported in previous large pharmacological trials, namely that ABP monitoring is a more powerful tool than office BP for the evaluation of antihypertensive drug efficacy [39] [40] [41] [42] . As a matter of fact ABP reflects true BP reduction during daily life, due to the lack of the white-coat and placebo effect, and to the phenomenon of the regression to the mean. This makes the antihypertensive response detected through ABP monitoring more precise and reliable than clinic measurements [39] .
When subgroup analyses, according to age and sex, were performed the antihypertensive efficacy of olmesartan over the 24 h was always greater than that of ramipril. However, statistically significant differences in favor of olmesartan were observed only for male patients and in the 65-69-year age group. It is likely that such differences could have occurred by chance, given the smaller number of patients included in each subgroup and the subsequent limited statistical power of the examined sample. Also the percentage of maximum drug dose was always larger in the ramipril treatment group, as in the whole study population.
Other reasons for such results are less likely, because previous studies have not disclosed any difference in the pharmacokinetics of olmesartan and ramipril according to sex or age [7, [43] [44] [45] .
We should emphasize that the present study has some limitations. First, the study is based on a post-hoc analysis of two original twin trials, being limited to a subgroup of patients with valid ABP recordings. However, this is an individual data analysis, providing information on the effect of antihypertensive treatment on 24-h ABP in elderly individuals that is not available elsewhere. Second, the antihypertensive effect of the maximum dose of ramipril employed in our study (10 mg) might not correspond to that of olmesartan (40 mg) . It is likely that ramipril at a higher dose than 10 mg may have a greater antihypertensive effect, but comparison had been made up to the maximum doses currently recommended for ramipril and olmesartan.
In conclusion, this large-scale, randomized, doubleblind, parallel-group, pharmacological trial demonstrated that olmesartan medoxomil provides an effective and longlasting control of hypertension in elderly patients with essential arterial hypertension. The BP-lowering effect is still evident and superior to that of ramipril in the hours farthest from last drug intake, which are considered at higher risk for cardiovascular events in this age category. Therefore, olmesartan might be considered as an effective and useful option among first-line drug treatments of elderly patients with essential arterial hypertension. All r were statistically significant (P < 0.0001).
